9/20/2013 11:15:43 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, presented data today at Cancer Advance at Harvard Medical School. Members of the Company’s management team participated in multiple panel discussions, and two posters describing ongoing clinical trials were presented. Verastem presented posters on the ongoing registration-directed COMMAND study in mesothelioma and the ongoing Phase 1/1b study of lead FAK inhibitor defactinib in combination with paclitaxel at the conference. “We are pleased to have initiated COMMAND and are aggressively opening sites worldwide,” said Robert Forrester, Verastem President and Chief Executive Officer. “Also, in the ongoing combination trial of defactinib and weekly paclitaxel in patients with ovarian cancer, paclitaxel was successfully combined with defactinib and we are encouraged by the early signs of clinical activity of the combination.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by